Brief: Paradigm Biopharmaceuticals Says Uk Ethics And Regulatory Approval For Phase 3 Study

Paradigm Biopharmaceuticals

17/03/2022 01:21

March 17 (Reuters) - Paradigm Biopharmaceuticals Ltd
 PAR.AX :
    * UK ETHICS AND REGULATORY APPROVAL FOR PHASE 3 STUDY-PAR.AX
    * NOW HAS ALL REQUIRED APPROVALS IN PLACE TO COMMENCE
CLINICAL
TRIAL SITE ACTIVATION IN UK FOR PARA_OA_002

Source text for Eikon:  ID:nASX3qvszs 
Further company coverage:  PAR.AX 

 ((Reuters.Briefs@thomsonreuters.com;))